Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer’s dementia: a pooled area under the curve analysis

INTRODUCTION: Treatment in moderate or severe Alzheimer’s disease (AD) often involves adding memantine to a cholinesterase-inhibitor (ChEI: donepezil, galantamine, rivastigmine). Evidence from six-month randomized trials and long-term observational studies supports superiority of memantine-ChEI comb...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Alzheimers Res Ther
Huvudupphovsmän: Atri, Alireza, Hendrix, Suzanne B, Pejović, Vojislav, Hofbauer, Robert K, Edwards, John, Molinuevo, José Luis, Graham, Stephen M
Materialtyp: Artigo
Språk:Inglês
Publicerad: BioMed Central 2015
Ämnen:
Research
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4436119/
https://ncbi.nlm.nih.gov/pubmed/25991927
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13195-015-0109-2
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk